Artwork

内容由Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel提供。所有播客内容(包括剧集、图形和播客描述)均由 Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

173 - Balancing Access and Safety: The FDA's Prescription Drug Risk Mitigation Strategy (REMS)

42:08
 
分享
 

Manage episode 381482071 series 70056
内容由Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel提供。所有播客内容(包括剧集、图形和播客描述)均由 Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, we will discuss the definition of REMS (Risk Evaluation and Mitigation Strategies), why they exist, the role of FDA in administering REMS, types and examples of REMS, and how they impact pharmacy practice.

Key Concepts

  1. The REMS (Risk Evaluation and Mitigation Strategies) program was developed in 2007 as part of the FDA’s drug risk management strategies designed to balance risk and benefits of certain drugs.
  2. Elements of REMS vary depending on the drug, but commonly include medication guides, communication plans, and other elements to assure safe use.
  3. REMS can require patients, providers, and pharmacies to take certain actions including training, registration, enrollment, safety monitoring, documentation of safety concerns, and follow prescribing and dispensing regulations.
  4. The FDA captures and assesses data on a regular basis to make changes in the REMS program. It also has authority to enforce compliance and take punitive actions against non-compliant parties.

References

  continue reading

198集单集

Artwork
icon分享
 
Manage episode 381482071 series 70056
内容由Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel提供。所有播客内容(包括剧集、图形和播客描述)均由 Sean P. Kane, PharmD, BCPS, Sean P. Kane, and PharmD; Khyati Patel 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

In this episode, we will discuss the definition of REMS (Risk Evaluation and Mitigation Strategies), why they exist, the role of FDA in administering REMS, types and examples of REMS, and how they impact pharmacy practice.

Key Concepts

  1. The REMS (Risk Evaluation and Mitigation Strategies) program was developed in 2007 as part of the FDA’s drug risk management strategies designed to balance risk and benefits of certain drugs.
  2. Elements of REMS vary depending on the drug, but commonly include medication guides, communication plans, and other elements to assure safe use.
  3. REMS can require patients, providers, and pharmacies to take certain actions including training, registration, enrollment, safety monitoring, documentation of safety concerns, and follow prescribing and dispensing regulations.
  4. The FDA captures and assesses data on a regular basis to make changes in the REMS program. It also has authority to enforce compliance and take punitive actions against non-compliant parties.

References

  continue reading

198集单集

すべてのエピソード

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南